Preparation for mastitis treatment in lactating cows

FIELD: medicine.

SUBSTANCE: said preparation contains the components as follows, %: Lincomycin hydrochloride 2.0-4.0; Dioxidine 0.5-1.0; soft Monoglyceride 3.0; distilled Monoglyceride 3.0; Vaseline oil to 100. The preparation is applied to treat all forms of mastitis in lactating period. Prior to introduction thereof, udder secretion is milked dry from an affected portion and utilised; a dug is disinfected. Before use, the contents of a syrette or a bottle is heated up to 37°C, agitated thoroughly to a uniform suspension, a sterile syringe is filled with 10 ml thereof from the bottle. The syringe or the syrette is tightly pressed to outer orifice of teat canal. The preparation is introduced therein by careful pressing the syringe piston. After introduction, gentle massage of the affected dug follows bottom-up. Considering the severity of inflammatory process, the preparation is introduced in a dose 10 ml once a day (preferentially, after afternoon milking) every 24 hours to ensure complete recovery of the affected dug portion. (2-4 times).

EFFECT: improved therapeutic effectiveness.

9 tbl, 5 ex

 

The invention relates to the field of veterinary medicine, in particular drugs for the treatment of mastitis in cows during lactation.

Mastitis - inflammation of the breast that occurs in response to adverse mechanical, physical, chemical and biological factors.

The main factors contributing to the emergence and development of mastitis, are the technical imperfection of milking, the violation of technological regulations of machine milking of cows. At the beginning of the irritation occurs, which when repeated repetition of moves in aseptic inflammation - the hidden mastitis. Reduced General and local (udder) resistance, the conditions for penetration and multiplication of different opportunistic and pathogenic organisms causing inflammation of various forms, ranging from subclinical proceeding independently for one, two lactations and leading share to atrophy, or transforming into clinically distinct (serous, catarrhal) mastitis etc.

Diseases of the mammary gland of cows are widespread and cause livestock large economic damage amounting to hundreds of millions of rubles. It consists of a shortfall of milk, premature culling of cows, the high incidence of young animals. All this violates rhythmically-flow production is the primary objective in milk, reduces production and economic efficiency of dairy cattle that adversely affects the provision of dairy products, the country's population. Therefore, the development of new and highly effective methods of treatment and prevention of mastitis in cows is relevant.

At present, domestic and foreign manufacturers produce drugs for the treatment of cows with mastitis, including antibiotics, sulfa, nitrofuranovye and other means. But not all of them give the desired effect, mainly because of decreased sensitivity to these tools microflora causing mastitis. This raises the need for new complex products with wide spectrum of action.

As similar to the proposed drug taken us Mastison And recommended for the treatment of mastitis in animals, contain potassium or sodium salt benzylpenicillin, streptomycin, norsulfazol or sulfadimezin, suspended in vegetable oil, in the following ratio of components, U and g/ml:

Sodium or potassium salt benzylpenicillin - 20000 IU/ml

Sulfate streptomycin - 20000 IU/ml

Norsulfazol or sulfadimezin - 0.004 g/ml

The oil base to 1 ml

The dose is 5-20 ml nipple in the cistern of the udder with interest the shaft 24 hours to fully cure [Veterinary drugs in Russia. The Handbook. M., 2004. Part 1. - S].

Known drug Mectizan B, containing in its composition:

Neomycin sulphate - 250 IU/ml

Sulfadimezin - 0,0035 g/ml

Methyluracil - 0,0035 g/ml

The oil base to 1 ml

[Antibiotics, sulfonamides and nitrofurans in veterinary medicine: a Handbook / Vffkauig, Ibilin and others - M.: Agropromizdat, 1988. - P.124].

Known drug Mectizan E, containing in its composition:

Erythromycin 11250 IU/ml

Sulfadimezin - 0.004 g/ml

The oil base to 1 ml

[Veterinary drugs in Russia. The Handbook. M., 2004. Part 1. - S].

Known drug dienogest. Dienogest - complex preparation containing gentamicin sulfate (2000 µg/g), dioxidine (1000 µg/g), beeswax and vaseline oil [Veterinary drugs in Russia. The Handbook. M., 2004. Part 1. - S].

A common disadvantage of known drugs is low therapeutic efficacy, since the application of repeated antibioticotherapy preparations formation of resistance to microorganisms. Most of the drugs produced in the form of suspensions during storage stratified, and vegetable oils are oxidized.

The prototype of the invention is a drug for the treatment of mastitis in cows during lactation, consisting of the following components (g / 100 ml): neomycin sulfate - 2, lincomycin hydrochloride,2 - monoglyceride soft - 3, the distilled monoglyceride - 3, oil - 100 [EN, 2180559, C1, 18.04.2002,].

This drug is not effective enough, because the combination of antimicrobial agents this drug provides only an additive effect.

The technical result of the invention is the improvement of therapeutic efficacy.

The technical result is achieved due to the use of lincomycin hydrochloride is a broad-spectrum antibiotic and dioksidina, effective for infections difficult to treat other antimicrobial means, in the form of a stable suspension in oil-based, not acting irritant to tissue of the udder.

Compared with the drug-the prototype of the salient features of the invention are the features that characterize the introduction part of the preparation of the broad-spectrum antibiotic of the lincomycin hydrochloride and chemotherapeutic drug - dioksidina, the lack of effective activity of other antibiotics. As emulsifiers in the basis of the drug entered the monoglyceride soft and distilled monoglyceride in an effective amount.

Drug for the treatment of mastitis in cows during lactation consists of the following components:

Lincomycin hydrochloride - 2,0-4,0%

Dioxidine - 0,5-1,0%

The monoglyceride soft - 3,0%

The monoglyceride dis is lirovannye - 3,0%

Vaseline oil up to 100%.

The achievement of the technical result of the proposed use of the drug due to the fact that part of the drug lincomycin hydrochloride is effective against most gram-positive coccoid (staphylococci, streptococci, pneumococci) and some gram-positive rod-shaped microorganisms, Mycoplasma and bacteria resistant to other antibiotics. Lincomycin inhibits the synthesis of protein in microbial cell by interacting with the SOS subunits of ribosomes. It blocks the formation of polyanaline functional complexes and broadcast transport-related RNA amino acids [Navashin S.M., Fomin I.P. Rational antibiotic therapy. M, "Medicine", 1982, p.146-149]. Included in the drug dioxidine refers to kinocilium row - 1,4-di-N-oxide-2,3-di(oxymethyl), cinoxacin exhibits high antimicrobial activity against gram-negative and gram-positive microorganisms. The greatest impact dioksidina susceptible gram-negative microorganisms ["Provisional guidance on the application of dioksidina in veterinary medicine". Decl. The main veterinary Department November 5, 1991].

Put in the basis of preparation the monoglycerides are used as emulsifiers and stabilizers in food fats, cosmetic creams, Pharma is efticiency ointments, plasticizers [Chemical encyclopedia. M.: Izd. "Owls. Encyclopedia", 1989, vol. 1, s-585].

The claimed drug use during lactation for the treatment of all forms of mastitis. Before the introduction of the drug udder secretions vydavat from the affected portion and disposed of, teats are disinfected. The contents of xprize tube or bottle before applying heated to 37°C, thoroughly shaken until a uniform suspension from the bottle trying to enter the sterile syringe 10 ml Syringe or syringe-tube tightly pressed to the outer hole of the nipple channel, the drug is injected into the nipple cistern of the udder carefully press the plunger of the syringe. After the introduction conduct a gentle massage the nipple of the affected part of the udder from the bottom up. Depending on the severity of the inflammatory process, the drug is administered in a dose of 10 ml once a day (preferably after the evening milking) with an interval of 24 hours to fully cure the affected part of the udder (2-4 times).

During treatment and for 3 days after the last injection of the drug milk from the affected lobe of the udder vydavat in a separate bowl, neutralized and disposed of, and of the remaining shares udder fed animals after boiling.

To obtain a disperse medium 6.0% of monoglycerides is dissolved at a temperature of 80°C in vaseline oil, added to 100%. The mixture autoclave at a temperature of 120°C during the 1.5-2 hours. Cooled to a temperature of 30-35°C basis contribute a portion of powders: lincomycin hydrochloride 2-4% and dioksidina 0.5 to 1%, pre-crushed in a ball mill, include a mixer for 15-20 minutes and pack up.

In appearance the product is a stable oily suspension viscous consistency with a specific smell, light yellow color with a greenish tint. At a temperature of 35°C, the suspension has a liquid consistency. The product is fully preserves the original properties (appearance, colour, authenticity, mass fraction dioksidina, mass fraction of lincomycin hydrochloride, microbial purity, mechanical inclusions) and not settled within 12 months of storage at a temperature of from 0 to 25°C.

Use in human consumption of milk is allowed 72 hours after the last injection, provided the complete disappearance of clinical signs of mastitis. Slaughter of animals for meat is allowed not earlier than 7 days after the last injection of the drug. Meat animals, forced killed earlier this term can be used for the production of meat and bone meal or in feed for fur animals.

Checking the efficiency of the drug was carried out on cows, belonging to JSC "Dolzhansky" Vagulevskogo district Belgorod region, JSC parties" Karachaevskogo district of Voronezh region, AND "Uspenskoe" ispk "Zdorovetchi" Livny region Orel region. The essence of the technical solution is illustrated by examples.

Example 1

To verify the effectiveness of the prototype of the invention was studied antimicrobial activity of lincomycin, neomycin and their combinations against major pathogens of mastitis. The results are presented in table 1.

Table 1
Antimicrobial activity of lincomycin, neomycin and their combinations against major pathogens of mastitis, ug/ml
№ p/pThe culture of a microbeLincomycin hydrochloridNeomycin sulfateLincomycin: neomycin 1:1
1Staphylococcus aureus-209 P12,512,512,5
2Streptococcus agalactiae-58612,525,012,5
3E. coli 013810012,525,0

About the Eden study of antimicrobial activity of this drug and its individual components has shown, the combination of antimicrobial agents this drug provides an additive effect, i.e. the total effect is equal to the sum of each component separately.

Example 2

To identify the optimal ratio of components and the effectiveness of the drug were prepared three recipes.

Recipe No. 1: dioxidine 1,0%; lincomycin 2,0%; distilled monoglyceride 3,0%; monoglyceride soft 3,0%; vaseline oil up to 100%.

Recipe 2: dioxidine 0,5%; lincomycin 4,0%; distilled monoglyceride 3,0%; monoglyceride soft 3,0%; vaseline oil up to 100%.

Recipe 3: dioxidine 0,75%; lincomycin of 3.25%; distilled monoglyceride 3,0%; monoglyceride soft 3,0%; vaseline oil up to 100%.

To determine the effectiveness of the proposed drug was selected 71 cow sick subclinical mastitis, divided according to the principle analogues into four groups. Animals of the first, second and third groups were subjected to the treatment offered by the drug (various formulations) in a dose of 10 ml once a day for 2-4 days, the fourth - ditomaso according to the instruction on its use. After 7-10 days the animals were examined clinically, and milk with 2% solution of masticina, settling probe that selectively by counting the number of somatic cells.

Table 2
therapeutic efficacy of the drug in subclinical mastitis
The farmTreatedThe concentrations of drugRecovery time, daysRecovered cowsCured shares
cowssharesQty%Qty%
Recipe 120232,23±0,12,5±0,121890,02295,6
Recipe 22024of 2.26±0,092,65±0,051890,02187,5
Rotz is round 3 36382,15±0,122,5±0,113597,23694,7
Dienogest35392,48±0,122,75±0,093188,53487,1
Table 3
therapeutic efficacy of the drug in catarrhal mastitis in cows
The farmTreatedThe concentrations of drugRecovery time, daysRecovered cowsCured shares
cowssharesQty%Qty%
R is capture 1 20243,28±0,05of 3.60±0,091785,02291,7
Recipe 220233,31±0,093,62±0,111890,02086,9
Recipe 325283,22±0,073,55±0,092392,02692,8
Dienogest24293,4±0,053,85±0,11984,22586,2

Table 4
Therapeutic effects of Yunosti of the drug in purulent-catarrhal mastitis in cows
The farmTreatedThe concentrations of drugRecovery time, daysRecovered cowsCured shares
cowssharesQty%Qty%
Recipe 110134,3±0,124,9±0,11880,01184,6
Recipe 21012of 4.49±0,124,87±0,11880,0975,0
Recipe 322264,2±0,114,7±0,1119 86,32388,5
Dienogest21244,7±0,15,5±0,121571,41875,0
Table 5
therapeutic effectiveness of cows with serous mastitis in cows
The farmTreatedThe concentrations of drugRecovery time, daysRecovered cowsCured shares
cowssharesQty%Qty%
Recipe 110142,9±0,113,61±0,009880,078,6
Recipe 210163,1±0,113,69±0,01880,01381,3
Recipe 321272,88±0,08the 3.65±0,091885,72281,5
Dienogest21293,15±0,113,85±0,11676,12275,8

As is seen in tables 2-5 data, a higher therapeutic effect has proposed drug (formulation 1; 2; 3) in comparison with ditomaso. The highest therapeutic effect has offered the drug formulation No. 3, the efficiency with subclinical mastitis reached 97.2%, catarrhal - 92,0%; purulent-catarrhal - 86,3%; sero - 85,7%, 8.7; 7,0; 9,6; 14.9 and 9.6% higher than in the treatment que what Omasta.

Thus, the high therapeutic effect is achieved by applying the following composition of the drug for the treatment of mastitis in cows in lactation period: dioxidine 0,75%; lincomycin of 3.25%; distilled monoglyceride 3,0%; monoglyceride soft 3,0%; vaseline oil up to 100%.

Example 3.

The influence of the drug (dioxidine 0,75%; lincomycin of 3.25%; distilled monoglyceride 3,0%; monoglyceride soft 3,0%; vaseline oil up to 100%) for the treatment of mastitis in cows on the mammary gland and the body of lactating cows was studied on three clinically healthy animals at 3-4 months of lactation, by intracisternal the introduction of the drug, warmed to 37°C in a dose of 10 ml in the left front portion of the udder, and the right front portion served as a control. After 3; 6; 12; 48 and 72 hours after drug administration cows were examined clinically, and samples were taken milk from these quarters of the udder to assess the reaction with 2% solution of masticina, determine the number of somatic cells (SC) and placing the sample solution.

The research results are summarized in tables 6 and 7.

Table 7
Influence intracisternal the introduction of the drug for the treatment of mastitis in cows during lactation on p the indicators of the General condition of an organism
The timeframe of the study hourIndicators
T°,PulseNumber of dehat. movements for 1 minNumber of abbr. scar for 5 min
Before the introduction of38,1±1,3to 70.7±0,7817,0±0,545,7±0,19
Through: 338,1±0,1671,0±0,0917,0±0,545,3±0,19
638,2±0,12from 71.3±1,5617,3±0,195,7±0,19
1238,0±0,12to 72.3±1,5618,0±0,396,7±0,19
2438,1±0,0875,3±1,5618,0±0,396,7±0,19
4838,1±0,0875,3±0,3918,7±0,396,0±0,39
7238,2±0,1676,3±0,9818,7±0,196,0±0,39

It was found that after intracisternal the introduction of the drug for the treatment of mastitis in cows during lactation in dose of 10 ml is an increase in the number of somatic cells (table 6) after 3 hours of 1.45 times (with 316,6±17.1 and 459,8±13,9 thousand/ml)after 6 h - 2.57; after 12 h, 3.9; after 24 h in 4,98; after 48 h at 2.22 times and 72 h approximates to the original level (368,9±30,4 thousand/ml). The reaction of the udder secretions with 2% solution of masticina within 48 hours was positive, and the test assertion is a negative. After intracisternal the drug is not installed noticeable changes from the General condition of the animals.

Thus, a drug for the treatment of mastitis during lactation has a mild irritant effect on the mammary gland of cows, the signs of which disappear within 72 hours after injection, and may be recommended for intracisternal injection for the treatment of mastitis in cows.

Example 4

Study of the antimicrobial action of the drug for the treatment of mastitis in cows during lactation (dioxidine 0,75%; lincomycin of 3.25%; distilled monoglyceride 3,0%; monoglyceride soft 3,0%; vaseline oil up to 100%) and its components conducted by the method of serial time is edeni in liquid nutrient medium. For conducting experiments used a pathogenic culture of microbes isolated from secret cows with mastitis, as well as the Museum strains.

The data for detection of antimicrobial activity are shown in table 8.

Table 8
Antimicrobial activity of a drug for treatment of mastitis in cows and its components against major pathogens of mastitis, IPC, ug/ml
№ p/pThe culture of a microbeLincomycinDioxidineDrug for the treatment of mastitis in cows
1Staphylococcus aureus-209 P12,525,06,3
2Staphylococcus aureus-5896,325,03,1
3Streptococcus agalactiae-58612,512,56,3
4Streptoco is to agalactiae-587 25,025,03,1
5Streptococcus agalactiae-58825,050,03,1
6Streptococcus gr. D-64010050,025,0
7E. coli 64310050,025,0

As can be seen from the presented data, the combination dioksidina in the ratio of 1:4 has a wide range and high antimicrobial activity against major pathogens of mastitis in a concentration of 3.1-25,0 mg/ml, which exceeds the antimicrobial activity dioksidina and lincomycin separately in 2-16 times.

In the study of antibacterial effect of the combination of lincomycin and dioksidina in vitro experiments we established that the minimum inhibitory concentration of each antibiotic in the presence of another is reduced considerably. For example, in the presence of lincomycin hydrochloride in a concentration of 2.51-5,12 ág/ml) minimum inhibitory concentration (MIC) dioksidina against Staphylococcus is ratestogo-R and Staphylococcus aureus-586 reduced to 0,59-1,18 g/ml (21.2%). Conversely, the presence in combination dioksidina at a concentration of 1.18 mg/ml reduces the IPC lincomycin up to 5,12 µg/ml (2.44-fold).

Adding to the dioksidin of lincomycin hydrochloride in a concentration of 2.51-5,12 µg/ml MBC first against Streptococcus agalactiae (strains 586; 587; 588) is reduced to 0,59-1,18 (21,0 is 84.7%). At the same time, the presence of dioksidin a concentration of 0.59-1,18 g/ml against this microorganism reduces IPC lincomycin up of 2.51-5,12 µg/ml (2,44-9.9 times).

Against Escherichia coli 643 and Streptococcus group D, in the presence of lincomycin at a concentration of 4.9 mg/ml, MBC dioksidina reduced to 10.6 ág/ml (4.9 times), and the presence of dioksidina at a concentration of 10.6 mg/ml in relation to these microorganisms reduces the IPC lincomycin hydrochloride to 4.9 µg/ml (10.6%).

The validity of this combination due to the fact that in the dosage form at the same time the combination of two antibacterial component. This provides synergenic effect due to the fact that both components are in the same phase of the cell growth, but in different metabolic pathways.

Dioxidine exhibits high antimicrobial activity against gram-negative and gram-positive microorganisms. The greatest impact dioksidina susceptible gram-negative microorganisms [Temporary instruction on the use dioksidina in vet is I. Decl. The main veterinary Department November 5, 1991]. Based antibacterial action dioksidina lies selective suppression of DNA synthesis. In addition, the drug reduces the activity of extracellular nucleases and plasmocoagulase in microorganisms, which leads to dysfunction of the genetic apparatus of microbial cells and result in suppression of synthesis of biologically active macromolecules, which are factors of pathogenicity.

Lincomycin is effective against most gram-positive coccoid (staphylococci, streptococci, pneumococci) and some gram-positive rod-shaped microorganisms, Mycoplasma and bacteria resistant to other antibiotics. Lincomycin inhibits the synthesis of protein in microbial cell by interacting with the SOS subunits of ribosomes. It blocks the formation of polyanaline functional complexes and broadcast transport-related RNA amino acids [Navashin S.M., Fomin I.P. Rational antibiotic therapy. M, "Medicine", 1982, p.146-149].

Example 5.

In production conditions shown in table 9 that the proposed drug in the combination of lincomycin hydrochloride and dioksidina achieve new sverhsummarny effect compared to one of the analogue medications (ditomaso).

Table 9
The effectiveness of treatment of cows with various forms of mastitis
TreatedThe concentrations of drugRecoveredCured
cowssharescows%shares%
Subclinical mastitis
Dienogest76922,6±0,16990,88188,0
Drug for the treatment of mastitis in cows during lactation79902,28±0,117493,78594,4
Catarrhal mastitis
Dienogest66793,48±0,135481,86582,2
Drug for the treatment of mastitis in cows during lactation66763,30±0,076192,46990,8
Purulent-catarrhal mastitis
Dienogest5262to 4.73±0,113873,14572,6
Drug for the treatment of mastitis in cows during lactation5563of 3.78±0,064785,55384,1
Serous mastitis
Dienogest 47673,5±0,193676,65176,1
Drug for the treatment of mastitis in cows during lactation48693,0±0,134083,35782,6

Thus, a drug for the treatment of mastitis in cows during lactation has higher compared to the prototype, therapeutic efficacy, due to the use of lincomycin hydrochloride is a broad-spectrum antibiotic and dioksidina, effective for infections difficult to treat other antimicrobial means, in the form of a stable suspension oil-based, not acting irritant to tissue of the breast.

Drug for the treatment of mastitis in cows during lactation containing the antibiotic lincomycin hydrochloride, as emulsifiers - monoglyceride soft and distilled monoglyceride and oil-based, characterized in that it further comprises dioxidine, and as oil fundamentals - vaseline oil the next time the ratio is AI components, %:

Lincomycin hydrochloride2,0-4,0
Dioxidine0,5-1,0
The monoglyceride soft3,0
The distilled monoglyceride3,0
Vaseline oil100



 

Same patents:

FIELD: medicine biologically active additives.

SUBSTANCE: According to the invention, the immunobiological bactericidal preparation contains species-specific virulent bacteriophages and induced-virulence bacteriophages of Appelman's lytic activity at least 10-4 with respect to test strains and bacteria isolates recovered from a human body in filtrate, concentrate filtrate or in a dry biomass of a phage lysate filtrate of nonlysogenic bacteria and pharmaceutically acceptable desired additives. The preparation can be presented as ointment, suppository, powder, tablet or capsule. Declared immunobiological bactericidal preparation is prepared by sequential multiple passages of phages of bacteriophage preparations through test strains and nonlysogenic bacteria isolates fresh-recovered from a human body with an inducing agent, eg mitomycin C, added to nutrient medium. According to the invention, the immunobiological bactericidal preparation provides stable virulence of bacteriophages and adaptation thereof to circular agents of bacterial infections.

EFFECT: higher clinical effectiveness.

13 cl, 9 tbl, 30 ex

FIELD: medicine; veterinary science.

SUBSTANCE: bacteriophage preparation as contains suspension of strains Phagum Salmonella typhimurium No.5 "ТЗ-ДЕП" of concentration 3.6×108 PFU/cm3 and Phagum Salmonella typhimurium No.8 "МЕ - ДЕП" of concentration 1.0×107 PFU/cm3 in equal relation in culture medium preserved in quinosol in the component ratio as follows (per 1 l of the culture medium): suspension of strain particles Phagum Salmonella typhimurium No.5 "ТЗ-ДЕП" - 3.6x108 PFU/cm3, suspension of strain particles Phagum Salmonella typhimurium No.8 "МЕ - ДЕП" - 1.0x107 PFU/cm3, quinosol - in end concentration 0.01%. Pigeons are fed with the preparation in a dose 0.25-0.5 ml every 48-72 h. The preparation may be added to potable water at 5-10 ml per 1 kg of body weight for one feeding. Before feeding, birds are kept without water for three hours.

EFFECT: preparation and related application method are safe, allow for effective treatment of salmonellosis infection, protect against said disease from first days of life, prevent postvaccinal complications and improve safety of livestock population.

4 cl, 2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention concerns pharmaceutical industry, food industry, bioengineering and can be used in manufacturing of medical immunobiological preparations, biologically active additives and food additives. The invention represents versions of the bacteriophage composition which contain species-specific virulent bacteriophages and induced-virulence bacteriophages of Appelman's lytic activity 10-4 with respect to test strains and bacteria isolates recovered from a human body in phage lysate filtrate of nonlysogenic bacteria or phage lysate concentrate filtrate of nonlysogenic bacteria, and desired additives.

EFFECT: invention provides stable virulence of bacteriophages, adaptation thereof to circular agents of bacterial infections.

6 cl, 2 tbl

FIELD: medicine.

SUBSTANCE: antibacterial agent selective effect contains action a bacteriophage concentrate, a herbal extract, a stabilising additive, an essence, an antioxidant, a preservative agent and prebiotics required for normal flora development - amino acid and sugar, as well as a sorbent and a protein-degrading enzyme in desired component ratio.

EFFECT: extended range of ecologically safe high-effective antibacterial agents.

5 cl, 2 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to operative obstetrics, and concerns integrated prevention of purulent-septic caesarean section complications that is ensured by intraoperative regional introduction of an antibiotic. Uterine cavity and abdominal cavity are irrigated with ozonised 0.9% normal saline of ozone concentration to 4 mg/l. During two postoperative days, ozonised 0.9% normal saline of ozone concentration 1-2 mg/l is introduced intravenously drop-by-drop in amount 400 ml. Starting from the end of the postoperative day, anterior vaginal fornix is exposed to low frequency pulse magnetic field generated by a vaginal inductor introduced therein for 15 minutes daily during 5-7 days.

EFFECT: method provides accelerated regress of pain syndrome, and involution of uterus, allows reducing introduction of antibiotics.

1 dwg, 2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine, infectious diseases and can be used for plague treatment in experiment. Method involves introduction to white mice of Streptomycin 2-2.5 mg as an antibiotic and Immunofan 0.2-0.3 mkg as an immunomodulator combined in the same syringe, in 72-76 hours after contamination with high-virulent strain Y.pestis 461 in a dose 1000000-200000 "м.к." in amount 0.1-0.3 ml of dissolver.

EFFECT: application of the invention allows improving clinical effectiveness of late-staged plague, providing eradication of the agent ensured by combined introduction of Streptomycin and Immunofan.

1 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention refers to versions of Neisseria, particularly meningococcal vesicular agents or vaccines produced of vesicles of outer membrane. There are also disclosed preferential methods and vaccine products based on application of new L2 immunotype LOS (lipooligosaccharides) and/or L3 immunotype LOS, including subunit vaccines or meningococcal vaccines produced of vesicles of outer membrane, as well as an immunogenic composition used for prevention or treatment of Neisseria-caused disease. There are described combined genes of negative regulation, such as PorA and OpA, PorA and OpC, OpA and OpC, PorA and OpA and OpC. It is alternatively or additionally shown that IgtB- represents an ideal mutation for effective and safe use of L3 and/or L2 LOS in Neisseria vaccine compositions. Besides, there are vesicular vaccines produced of IgtB- and meningococcal mutants, defective in capsular-like polysaccharide, as well as preferential methods for preparing the vesicular agents, where LOS shall be preserved as a constitutive antigen.

EFFECT: agents prepared under the present invention are safer and/or more effective for human application.

29 cl, 12 dwg, 1 tbl, 11 ex

FIELD: medicine.

SUBSTANCE: invention concerns medicine, namely to treatment of infectious diseases and can be used for treatment of a bacteriemic infection. The way is performed as follows. Daptomicin is administered to the person in a dose from 3 mg/kg to 75 mg/kg, repeatedly in a period from once every 24 hours to once a week. Invention use allows minimising daptomicin toxicity to sceletal muscles at its administration in the increased doses, at the expense of interval increase between administration of the specified doses.

EFFECT: minimised daptomicin toxicity to sceletal muscles at its administration in the increased doses, at the expense of interval increase between administration of the specified doses.

27 cl, 5 tbl, 3 dwg, 4 ex

FIELD: medicine, veterinary science.

SUBSTANCE: group of inventions concerns veterinary science and biotechnology area. The way of reception of a brucellous antigen from the Brucella abortus 19 strain for manufacturing of a uniform brucellous antigen for AA, CFR and LCFR includes reception of an inoculum and propagation of brucellas in deep conditions on a liquid nutrient medium with regulation of level of partial pressure of oxygen dissolved in a culture liquid throughout all propagation process, separation and concentration of evolved bacteriemic cells using ultrafiltration and their inactivation using warming. Thus brucellas propagation in deep conditions on a liquid nutrient medium with regulation of level of partial pressure of oxygen dissolved in a culture liquid throughout all propagation process is performed in a following regimen: temperature 37±0.5°C, pH 6.9-7.2 aeration from 1 hour till 3 hour - 20-25 pO2, from 3 hour till 6 hour - 25-40 pO2, from 6 hour till 15 hour - 40-45 pO2 and from 15 hour till 16-18 hour - 30-35 pO2. Separation and concentration of the evolved bacteriemic cells by ultrafiltration is carried out with use of membranous cartridges. The concentrate of an antigen received by given way is used also for reception of an antigen for Rose Bengal Assay (RBA), for reception of a brucellous antigen for ring test (RT) with milk and reception of diagnostic brucellous serum which, together with blood serum of healthy livestock, make a part of sets for brucellosis diagnostics. The group of inventions allows to raise efficiency of process of brucellosis diagnostics and to improve control at serologic examination of animals.

EFFECT: rising of efficiency of process of brucellosis diagnostics and improvement of control at serologic examination of animals

22 cl, 11 ex

FIELD: medicine.

SUBSTANCE: way concerns medicine, namely to urology, and concerns treatment of the complicated clamidiosis of a urogenital tract of women and men. For this purpose azithromycin is entered slowly intravenously driply in a dose of 500 mg during 2-2.5 h. Introduction of azithromycin is performed on 1, 7 and 14 days of treatment. The way provides high therapeutic efficiency and prevention of relapses of disease at use of azithromycin in small doses, and also allows avoiding complications from a GI tract.

EFFECT: provision of high therapeutic efficiency and the prevention of relapses of disease at use of azithromycin in small doses, and also reception of possibility to avoid complications from a GI tract.

2 ex

FIELD: agriculture; veterinary science.

SUBSTANCE: application of cysteamine, its salt or composition, containing cysteamine or its salt, stabilizer and/or coated carrier to improve lactation of the milking animals, particularly cows.

EFFECT: increases milk yield, its fat and protein content.

42 cl, 24 tbl, 1 dwg

FIELD: organic chemistry, medicine, biochemistry, pharmacy.

SUBSTANCE: invention relates to compounds of the general formula (I): wherein R1 represents (C1-C4)-alkyl with branched or linear chain; R2 represents hydrogen atom (H); R3 represents (C1-C4)-alkyl with branched or linear chain; R4 represents (C1-C4)-alkyl with branched or linear chain, (C2-C4)-alkenyl; R5 represents -SO2NR10R11; R8 represents (C1-C4)-alkyl with branched or linear chain; each R10 and R11 represents independently H or (C1-C12)-alkyl with branched or linear chain; or R10 and R11 in common with nitrogen atom to which they are bound form pyrrolinone group, piperidyl, morpholinyl, 4-N(R13)-piperazinyl that are substituted optionally with (C1-C4)-alkyl with branched or linear chain, -NR14R15, phenyl group substituted optionally with -OH or phenyl group bound in common with other substituted phenyl group by carbonyl group; R13 represents (C1-C4)-alkyl with branched or linear chain, (C2-C6)-alkyl with branched or linear chain and substituted with hydroxyl; (C2-C6)-alkyl with branched or linear chain substituted with phenyl; (C2-C6)-hydrocarbon with branched or linear chain substituted with -CO2R8; wherein each radical among R14 and R15 represents independently H; (C1-C4)-alkyl with branched or linear chain, or its pharmaceutically acceptable salt. The claimed compounds possess inhibitory effect on activity of phosphodiesterase-5 and can be used for production of drug for treatment or prophylaxis of diseases associated with phospholipase and its function. Also, invention relates to pharmaceutical composition, medicinal composition for veterinary science, and intermediate compounds IA-IG used for synthesis of compound of the formula (I).

EFFECT: valuable medicinal and biochemical properties of compounds and pharmaceutical composition.

8 cl, 2 tbl, 4 ex

FIELD: veterinary science.

SUBSTANCE: the present innovation refers to medicinal preparations applied for treating puerperal purulent-catarrhal endometritis and mastitis in cows and to the method of applying the present medicinal preparations. The suggested preparation for treating puerperal purulent-catarrhal endometritis, serous, seroso-catarrhal and subclinical mastitis in cows includes 1.4-di-N-oxide 2.3-bis-(oxymethyl) quinoxaline, trecresan (cresacin), dimethyl sulfoxide, propandiol 1.2 at the following ratio, (g/%): 1.4-di-N-oxide 2.3-bis-(oxymethyl) quinoxaline 1.0-1.2; trecresan (cresacin) 3.0-3.18; dimethyl sulfoxide 10.0-10.5; propandiol 1.2 20-25; distilled water - the rest. The innovation deals with intra-uterine introduction of the preparation suggested at the dosage of about 70-100 ml once daily for about 4-5 d. Moreover, this preparation should be introduced into affected part of the udder at the dosage of 10 ml once daily for 3-5 d. The innovation enables to shorten the multiplicity of introduction and accelerate the terms of recovery.

EFFECT: higher efficiency of therapy.

4 cl, 2 ex, 6 tbl

FIELD: organic chemistry, chemical technology, medicine.

SUBSTANCE: invention relates to new derivatives of pyrrolopyrimidine of the formula (1) and their pharmaceutically acceptable salts possessing properties of selective inhibitor of specific cyclic guanosine 3',5'-monophosphate phosphodiesterase (specific cGMP PDE) (PDE V). In the formula (1) R1 represents hydrogen atom (H), (C1-C3)-alkyl substituted optionally with one or some fluorine atoms; R2 represents H, halogen atom, (C1-C6)-alkyl substituted optionally with hydroxyl group (-OH), (C1-C3)-alkoxy-group, (C3-C6)-cycloalkyl or one or some fluorine atoms, (C3-C6)-cycloalkyl; R3 represents (C1-C6)-alkyl substituted optionally with (C3-C6)-cycloalkyl or one or some fluorine atoms; R4 represents (C1-C6)-alkyl substituted optionally with one or some fluorine atoms; R5 represents -SO2NR6R, -NHSO2R8 or heterocyclyl such as tetrazolyl; each R6 and R7 represents independently H or (C1-C6)-alkyl substituted optionally with -CO2H or one or some fluorine atoms; or in common with nitrogen atom to which they are bound form monocylic ring, such as imidazole, pyrrolidine, piperidine, morpholine, piperazine and homopiperazine wherein indicated group is replaced optionally with R9 wherein R9 represents (C1-C6)-alkyl substituted optionally with one or some halogen atoms, hydroxyl group (OH), (C1-C3)-alkoxy-group that is replaced optionally with one or some fluorine atoms, -NR11R12, -C=NR13(NR14R15) or tetrazolyl group, 6-membered nitrogen-containing heteroaryl group; each R11 and R12 represents independently H or (C1-C4)-alkyl; R13represents H; each R14 and R15 represents independently H. Also, invention relates to intermediate compounds, methods for preparing compounds and pharmaceutical compositions. Proposed compounds can be used in treatment of impotency, sexual dysfunction in females, stable, nonstable and variant (Prinzmental) stenocardia and other diseases also.

EFFECT: improved preparing method, valuable medicinal properties of compounds.

15 cl, 1 tbl, 250 ex

FIELD: veterinary science.

SUBSTANCE: one should apply liniment that contains an active substance being "Todicamp-ideal" and a vegetable foundation as a mustard-pumpkin fuse obtained while manufacturing "Volgogradskoe" vegetable oil at weight ratio of mustard and pumpkin oils being 1:9 weight portions. Moreover, "Todicamp-ideal" and mustard-pumpkin fuse are at weight ratio of 10-12 : 90-88 weight portions. In some cases of liniment application upon affected part of cow's udder should be combined with peroral intake of "Todicamp-ideal". The innovation provides simultaneous antiphlogistic, antimicrobial and immunostimulating effect.

EFFECT: higher efficiency of therapy.

2 cl, 2 ex, 1 tbl

FIELD: veterinary science.

SUBSTANCE: a sow should be twice injected with oxytocin and, additionally, intramuscularly about 2-4 h after afterbirth detachment one should introduce clathroprostin at the dosage of 1 ml. The innovation suggested is very efficient in preventing metritis-mastitis-agalactia and endometritis in sows, as well.

EFFECT: higher efficiency of prophylaxis.

1 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: invention concerns medicinal agents, particularly application as an agent for correction of female reproductive dysfunction caused by cytostatic exposure, namely a preparation thio-fan-bis-1[(3,5-di-tert-butyl-4-hydroxyphenyl)propyl]sulphide which is a sulphur phenolic antioxidant.

EFFECT: problem to be solved by said invention is extended range of the therapeutic agents used for correction of female reproductive dysfunction caused by cytostatic exposure with reduction of by-effects.

3 dwg, 1 ex

FIELD: veterinary science.

SUBSTANCE: invention relates to veterinary science, precisely to obstetrics, genecology and biotechnology of reproduction, mainly to medicines for treatment of animals with puerperal endometritis. The medicine contains ethacridine lactate - 0.6, aloe - 50.4; cephatoxime - 2, urea - 15.0; neutral formalin - 10; distilled water - 5; glycerine - 17.0.

EFFECT: medicine has anti-inflammatory and antibacterial effects.

2 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to operative obstetrics, and concerns integrated prevention of purulent-septic caesarean section complications that is ensured by intraoperative regional introduction of an antibiotic. Uterine cavity and abdominal cavity are irrigated with ozonised 0.9% normal saline of ozone concentration to 4 mg/l. During two postoperative days, ozonised 0.9% normal saline of ozone concentration 1-2 mg/l is introduced intravenously drop-by-drop in amount 400 ml. Starting from the end of the postoperative day, anterior vaginal fornix is exposed to low frequency pulse magnetic field generated by a vaginal inductor introduced therein for 15 minutes daily during 5-7 days.

EFFECT: method provides accelerated regress of pain syndrome, and involution of uterus, allows reducing introduction of antibiotics.

1 dwg, 2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to gynaecology, and concerns chronic adnexitis treatment that is ensured by course of general hydrogen sulphide baths of temperature 36-37°, concentration of 50-140 mg/l, within 8-10 minutes, 6-8 baths every second day and gynaecologic irrigations at temperature 38°, concentration to 140 mg/l, within 10-12 minutes for course 6-8 daily procedures. Panties-like applications of sulphide silt mud are performed at temperature 38-42°, within 10-15 minutes every second day. Additionally, there are applied vulval pads with ointment Ephthypeloid U containing as follows, wt %,: diclofenac - 0.5, furasolidone - 0.5, metronidazole - 0.1, Lydasa PE - 2 PE, tetracycline - 0.8, erythromycin - 0.5, nystatin - 0.5 g 500000 units - 1.0, calendula extract - 0.3, chestnut extract - 0.3, dalargin - 0.2, Solbrol M - 0.2, Solbrol P - 0.06, Solbrol BR - 0.3, Extrapone V - 0.16, Eftillin - 40.0 and sulphide silt mud of Suksunsky pond - 55.0 in amount 2-2.5 ml for 6-7 hours daily within course 6-8 procedures.

EFFECT: method provides intensified and accelerated complex analgetic, antiinflammatory, antimicrobic action of Ephthypeloid U components and as consequence, normalisation of microcirculation and acceleration repair processes.

8 ex

Up!